Compare Marriott International Inc (MAR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Marriott International Inc trades at $363.33 (market cap $94.16B), while Vertex Pharmaceuticals Incorporated trades at $508.7 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Marriott International Inc pays a 0.81% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MAR | VRTX | |
|---|---|---|
Market Cap | $94.16B | $127.55B |
Volume | 996,176 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $557.96 |
52-Week Low | $259.04 | $407.37 |
Typical Hold Time | 164 Days | 120 Days |
Enterprise Value | $111.47B | $121.68B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $356.5, down 1.32% on the day, with a bullish technical signal supported by moving averages. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%. Recent earnings beat expectations in Q1 and Q2 2026, while Q3 results are pending. The company maintains strong cash flow from operations at $3.21B and announced a dividend of $0.73 per share payable in September 2026.
The outlook is positive with a consensus price target of $386.71, implying upside. Risks include high debt levels and competitive pressures. Analyst sentiment is mixed with 44% buy ratings, but institutional interest remains strong, supporting a cautiously optimistic view for long-term investors.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
